CTI BioPharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	1,623	1,634	1,592	1,364	1,152
Revenue Growth (YoY)	-	2.69%	16.67%	18.37%	-
Cost of Revenue	1,194	1,201	1,212	1,129	942.8
Gross Profit	428.93	433.55	379.42	234.79	209.62
Selling, General & Admin	171.53	162.59	130.98	117.49	101.09
Other Operating Expenses	18.24	19.61	22.87	20.3	14.43
Operating Expenses	189.77	182.2	153.85	137.79	115.51
Operating Income	239.16	251.35	225.57	97	94.11
Interest Expense	-25.75	-25.04	-13.22	-17.89	-21.01
Interest & Investment Income	1.47	1.47	0.95	0.44	0.47
Earnings From Equity Investments	-	-	-	0.27	-0.68
Currency Exchange Gain (Loss)	-43.23	12.17	-8.7	7.73	28.84
Other Non Operating Income (Expenses)	45.04	-16.33	-2.23	-7.86	-27.16
Pretax Income	216.69	223.62	202.38	79.69	74.56
Income Tax Expense	55.96	57.54	47.13	16.97	15.34
Net Income	160.73	166.07	155.24	62.72	59.22
Net Income to Common	160.73	166.07	155.24	62.72	59.22
Net Income Growth	-	6.98%	147.51%	5.91%	-
Shares Outstanding (Basic)	179	175	175	175	175
Shares Outstanding (Diluted)	179	175	175	175	175
Shares Change (YoY)	1.98%	-	-	0.01%	-
EPS (Basic)	0.90	0.95	0.89	0.36	0.34
EPS (Diluted)	0.90	0.95	0.89	0.36	0.34
EPS Growth	-	6.98%	147.52%	5.90%	-
Free Cash Flow	90.21	112.62	109.98	53	84.43
Free Cash Flow Per Share	0.50	0.64	0.63	0.30	0.48
Gross Margin	26.43%	26.53%	23.84%	17.21%	18.19%
Operating Margin	14.74%	15.38%	14.17%	7.11%	8.17%
Profit Margin	9.90%	10.16%	9.75%	4.60%	5.14%
Free Cash Flow Margin	5.56%	6.89%	6.91%	3.89%	7.33%
EBITDA	328.34	335.11	301.05	174.1	166.44
EBITDA Margin	20.23%	20.50%	18.92%	12.76%	14.44%
D&A For EBITDA	89.19	83.76	75.48	77.1	72.33
EBIT	239.16	251.35	225.57	97	94.11
EBIT Margin	14.74%	15.38%	14.17%	7.11%	8.17%
Effective Tax Rate	25.82%	25.73%	23.29%	21.30%	20.57%

Updated Jul 29, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q